| pubmed-article:6750250 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6750250 | lifeskim:mentions | umls-concept:C0005961 | lld:lifeskim |
| pubmed-article:6750250 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:6750250 | lifeskim:mentions | umls-concept:C0035020 | lld:lifeskim |
| pubmed-article:6750250 | lifeskim:mentions | umls-concept:C1515895 | lld:lifeskim |
| pubmed-article:6750250 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6750250 | pubmed:dateCreated | 1982-12-2 | lld:pubmed |
| pubmed-article:6750250 | pubmed:abstractText | The results of allogeneic marrow transplantation in 75 patients with acute lymphoblastic leukemia and 63 patients with acute non-lymphoblastic leukemia in relapse are reviewed. The effects of various chemotherapeutic regimens added to the basic regimen of cyclophosphamide (Cy) 60 mg/kg given on each of two successive days followed by 1000 rad of total body irradiation (TBI) were evaluated. The regimens tested were dimethylbusulphan (DMB), 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) and daunorubicin. Seventeen of 138 patients are alive between three and nine and a half years from transplantation. The addition of other chemotherapeutic agents to th basic Cy and TBI regimen did not decrease relapse frequency or prolong survival. | lld:pubmed |
| pubmed-article:6750250 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6750250 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6750250 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6750250 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6750250 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6750250 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6750250 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6750250 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6750250 | pubmed:issn | 0145-2126 | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:StorbRR | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:ThomasE DED | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:BucknerC DCD | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:CliftR ARA | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:SandersJ EJE | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:FlournoyNN | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:ShulmanHH | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:StewartP SPS | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:SullivanK MKM | lld:pubmed |
| pubmed-article:6750250 | pubmed:author | pubmed-author:BadgerCC | lld:pubmed |
| pubmed-article:6750250 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6750250 | pubmed:volume | 6 | lld:pubmed |
| pubmed-article:6750250 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6750250 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6750250 | pubmed:pagination | 383-7 | lld:pubmed |
| pubmed-article:6750250 | pubmed:dateRevised | 2007-11-15 | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:meshHeading | pubmed-meshheading:6750250-... | lld:pubmed |
| pubmed-article:6750250 | pubmed:year | 1982 | lld:pubmed |
| pubmed-article:6750250 | pubmed:articleTitle | Allogeneic marrow transplantation for acute leukemia in relapse. | lld:pubmed |
| pubmed-article:6750250 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6750250 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:6750250 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6750250 | lld:pubmed |
